(Q45008293)

8 December 2017

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. (English)

1 reference

8 December 2017

1 reference

Yuhong Zhou

1

1 reference

8 December 2017

Haijun Wang

2

1 reference

8 December 2017

Wenjing Fang

3

1 reference

8 December 2017

Jorge E Romaguer

4

1 reference

8 December 2017

Yanxia Zhang

5

1 reference

8 December 2017

Kay B Delasalle

6

1 reference

8 December 2017

Larry Kwak

7

1 reference

8 December 2017

Qing Yi

8

1 reference

8 December 2017

Xianglin L Du

9

1 reference

8 December 2017

Michael Wang

10

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

8 December 2017

1 reference

8 December 2017

113

1 reference

8 December 2017

791-798

1 reference

8 December 2017

4

1 reference

Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution

8 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Mantle-cell lymphoma: a population-based clinical study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countries.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Distribution of various subtypes of non-Hodgkin's lymphoma in India: A study of 2773 lymphomas using R.E.A.L. and WHO Classifications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Non-Hodgkin’s Lymphomas in Greece according to the WHO Classification of Lymphoid Neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Use of the WHO lymphoma classification in a population-based epidemiological study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Expert Review of Non-Hodgkin's Lymphomas in a Population-Based Cancer Registry: Reliability of Diagnosis and Subtype Classifications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Increasing incidence and mortality of non-Hodgkin lymphomas. An epidemiological review of recent studies on risk factors for non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23608

7 January 2021

Identifiers

DOI

10.1002/CNCR.23608

1 reference

8 December 2017

1 reference